Metabolic syndrome.
10.5124/jkma.2012.55.10.1005
- Author:
Mi Kyung KIM
1
;
Jeong Hyun PARK
Author Information
1. Department of Internal Medicine, Inje University College of Medicine, Busan, Korea. pjhdoc@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Metabolic syndrome;
Pathophysiology;
Therapeutics;
Pharmacology
- MeSH:
Adult;
Cardiovascular Diseases;
Cholesterol;
Diabetes Mellitus, Type 2;
Dyslipidemias;
Glucose;
Humans;
Hypertension;
Insulin Resistance;
Obesity, Abdominal
- From:Journal of the Korean Medical Association
2012;55(10):1005-1013
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Metabolic syndrome is defined as the simultaneous presence of central obesity, glucose abnormality, hypertension, and dyslipidemia, with the assumption that these entities share insulin resistance as a common pathophysiology. National Cholesterol Education Program Adult Treatment Panel III and International Diabetes Federation guidelines have led to uniformity and standardization of the definition of metabolic syndrome, but some confusion and controversy remains. The clinical relevance of metabolic syndrome is related to its role in the development of cardiovascular disease and type 2 diabetes mellitus. This article provides a comprehensive discussion on the pathophysiologic basis and the pharmacologic treatments for metabolic syndrome. We do not yet have specific pharmacologic treatments for the essential pathophysiologies of metabolic syndrome, so meticulous control of each component is required.
